Study of Acetazolamide to Improve Drive-Dependent Obstructive Sleep Apnea in Adults Aged 21 to 80

What this Trial Is About

Obstructive sleep apnea OSA is a common disorder that affects heart health, brain function, daytime alertness, and overall quality of life. Researchers are studying a new model called drive-dependent OSA, which involves unstable breathing control that can sometimes help keep the airway open during sleep. This study aims to see if the drug acetazolamide can improve OSA severity in people with drive-dependent OSA compared to those with classic OSA by stabilizing breathing control during sleep. Participants will receive acetazolamide or a placebo for three nights each in a randomized order, with a half dose on the first night and full doses on the next two nights. After each treatment period, they will stay overnight in a sleep lab for detailed assessments. There is a one-week gap between treatments. Following this, a four-week open-label extension will check if acetazolamides effects continue with repeated use without invasive testing. Throughout the study, participants will take part in sleep studies that measure breathing, muscle activity, and brain arousals. These include routine and specialized sleep tests with advanced monitoring of breathing drive and airway muscle function. Researchers will track changes in apnea events, oxygen levels, and sleep quality, and carefully record any side effects. The total participation includes screening, two treatment periods, and a month-long extension to evaluate ongoing effects and symptoms.

Acetazolamide as a Means to Mitigate Falling Ventilatory Drive and Drive-dependent OSA